| HOME >> MEDICINE >> TECHNOLOGY |
Table 4.7 Novartis: Key Facts, 2012
Table 4.8 Novartis: Antibacterial Revenue, 2009-2011
Table 4.9 Novartis: Antibacterial SWOT Analysis, 2012-2022
Table 4.10 Novartis: Antibacterial Revenue Forecast, 2011-2022
Table 4.11 Bayer: Key Facts, 2012
Table 4.12 Bayer: Antibacterial Revenue, 2009-2011
Table 4.13 Avelox: Patent Expiries by Country, 2013-2015
Table 4.14 Bayer: Antibacterial SWOT Analysis, 2012-2022
Table 4.15 Bayer: Antibacterial Revenue Forecast, 2011-2022
Table 4.16 AstraZeneca: Key Facts, 2012
Table 4.17 AstraZeneca: Antibacterial Revenue, 2008-2011
Table 4.18 AstraZeneca: Antibacterial SWOT Analysis, 2012-2022
Table 4.19 AstraZeneca: Antibacterial Revenue Forecast, 2011-2022
Table 4.20 Roche: Key Facts, 2012
Table 4.21 Roche: Antibacterial Revenue, Q1-Q4 2011
Table 4.22 Roche: Antibacterial Revenue by Region, Q1 2012
Table 4.23 Roche: Antibacterial SWOT Analysis, 2012-2022
Table 4.24 Roche: Antibacterial Revenue Forecast, 2011-2022
Table 5.1 Daiichi Sankyo: Key Facts, 2012
Table 5.2 Daiichi Sankyo: Antibacterial Revenue, FY 2006-2011
Table 5.3 Daiichi Sankyo: Antibacterial SWOT Analysis, 2012-2022
Table 5.4 Daiichi Sankyo: Antibacterial Revenue Forecast, 2011-2022
Table 5.5 Shionogi: Key Facts, 2012
Table 5.6 Shionogi: Antibacterial SWOT Analysis, 2012-2022
Table 5.7 Shionogi: Antibacterial Revenue Forecast, 2011-2022
Table 5.8 Meiji Seika Pharma: Key Facts, 2012
Table 5.9 Meiji Seika Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.10 Meiji Seika Pharma: Antibacterial Revenue Forecast, 2011-2022
Table 5.11 Astellas Pharma: Key Facts, 2012
Table 5.12 Astellas Pharma: Leading Antibacterial Drug Revenue, FY 2007-2011
Table 5.13 Astellas Pharma: Antibacterial SWOT Analysis, 2012-2022
Table 5.14 Astellas Pharma: Antibacterial R
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |